Immunogenic compositions and methods for pigeon fever
View Patent ↗The disclosure provides for immunogenic compositions against Pigeon Fever, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include other equine pathogens.
1. An immunogenic composition of one or more isolates of inactivated Corynebacterium Pseudotuberculosis isolate deposited with the ATCC under Accession no. PTA-121358.
2. The immunogenic composition of claim 1 in which the isolate, prior to inactivation, grows in cell culture to at least 10 8 CFU/mL.
3. The immunogenic composition according to claim 1 , wherein any of the isolates are present in an amount from about 10 2.0 CFU/mL-10 8.0 CFU/mL per dose.
4. The immunogenic composition according to claim 1 , wherein said immunogenic composition further comprises a suitable pharmaceutical carrier.
5. The immunogenic composition according to claim 4 , wherein said suitable pharmaceutical carrier is selected from the group consisting of a diluent, a carbomer adjuvant, antimicrobial agent, preservative, inactivating agent, and combinations thereof.
6. A method for reducing the incidence or lessening the severity of clinical symptoms associated with or caused by Corynebacterium pseudotuberculosis in horses or a herd of horses, comprising the step of administering the immunogenic composition according to claim 1 to a horse or herd of horses in need thereof.
7. The method according to claim 6 , wherein any of the isolates are present in an amount from about 10 6 CFU/mL-10 11 CFU/mL per dose for bacterium.
8. The method according to claim 6 , wherein said immunogenic composition further comprises a suitable pharmaceutical carrier.
9. The method according to claim 8 , wherein said suitable pharmaceutical carrier is selected from the group consisting of a diluent, a carbomer adjuvant, antimicrobial agent, preservative, inactivating agent, and combinations thereof.
10. The method according to claim 9 , wherein said immunogenic composition is administered in one or more doses.
11. The method according to claim 10 , wherein one dose of said immunogenic composition is formulated in a dosage form of 0.5 mL to 2.5 mL.
12. The method according to claim 9 , wherein said immunogenic composition is safe for use in foals or horses 4 months of age or older.
13. A method for producing an immunogenic composition comprising one or more isolates of inactivated Corynebacterium Pseudotuberculosis , the method comprising:
a) growing a virulent Corynebacterium pseudotuberculosis organism in growth media which allows high CFU/mL titer and high Phospholipase D production by the virulent Corynebacterium pseudotuberculosis organism;
b) harvesting the organism, phospholipase D and media;
c) contacting the organism, phospholipase D, and media culture with an inactivating agent to obtain the inactivated Corynebacterium Pseudotuberculosis Bacterin-Toxoid,
d) filtering the inactivated culture in said media to yield a substantially purified Corynebacterium Pseudotuberculosis organism and phospholipase D toxoid; and
e) said Corynebacterium pseudotuberculosis isolate is ATCC Accession No. PTA-121358.
14. An immunogenic composition comprising a Corynebacterium pseudotuberculosis isolate having ATCC Accession No. PTA-121358 and Amphotericin B, gentamicin sulfate, formaldehyde, and an adjuvant.
15. The method of claim 13 further comprising adding an adjuvant and one or more preservatives.